Table 2.

Risk features in OPLs with minimal or no dysplasia

AllToluidine blue–negativeToluidine blue–positiveP
Number of lesions836320
Clinical features
    Located at high-risk sites (%) *44 of 83 (53%)33 of 63 (52%)11 of 20 (55%)1
    Largest dimension (mean ± SD) at start of study15 ± 1214 ± 1018 ± 160.74
    Largest dimension (mean ± SD) during follow-up20 ± 1518 ± 1327 ± 190.028
    Nonhomogeneous lesions at start of study (%)23 of 83 (28%)13 of 58 (22%)10 of 19 (53%)0.02
    Nonhomogeneous lesions during follow-up (%)40 of 83 (48%)25 of 62 (40%)12 of 20 (75%)0.0097
Molecular features
    OPLs with LOH6246 of 63 (73%)16 of 20 (80%)0.77
    OPLs with LOH > 1 arm2517 of 63 (27%)8 of 20 (40%)0.28
    OPLs with LOH > 2 arms137 of 63 (11%)6 of 20 (30%)0.072
    Low risk pattern (retention of 3p and 9p)4335 of 63 (56%)8 of 20 (40%)0.31
    High-risk pattern (3p and/or 9p LOH plus other arm) 179 of 63 (14%)8 of 20 (40%)0.023
Outcome
    OPLs progressing to cancer8 of 83 (10%)3 of 63 (5%)5 of 20 (25%)0.0177
  • * Site at high-risk for cancer progression: floor of mouth, ventrolateral tongue.

  • Based on Rosin et al. ( 10). Relative risk for low-risk was 1, and high risk 33.4.

  • Includes loss at evaluated loci on 4q, 8p, 11q, 13q, or 17p.